New and classical antidiabetics in 2018
Authors:
M. Prokeš; J. Suchopár
Authors place of work:
DrugAgency, a. s.
Published in the journal:
Reviz. posud. Lék., 21, 2018, č. 3-4, s. 71-82
Category:
Original Articles, Review Articles, Case Reports
Summary
leave the position of the safe and most prescribed antidiabetics. New drug groups come with different mechanisms of action, so doctors can better choose medication for their patients better than before, but only when will learn not only the benefits of the medicines but also their risks. Drug interactions of antidiabetics, as like in other drug groups, may increase or decrease the effect of the active ingredients or to harm the patients in a different way.
Keywords:
antidiabetics – sulfonylureas – DPP-4 inhibitors – pioglitazone – SGLT2 inhibitors – Drug-drug interactions
Zdroje
1. Pelikánová, T. Léčiva používaná k terapii diabetu. In: Suchopár, J. et al. Compendium – Léčiva používaná v podmínkách ČR, 5. vydání, s. 567–592.
2. Škrha, J., Pelikánová, T., Kvapil, M. Diabetes mellitus (za Českou diabetologickou společnost ČLS JEP). Doporučený postup péče o diabetes mellitus 2. typu. Dostupné na www: http://www.diab.cz/dokumenty/standard_lecba_dm_typ_II.pdf.
3. Dujic, T., Zhou, K., Donnelly, L. A. et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes, 2015, 64(5), s. 1786–1793.
4. Maedler, K., Carr, R. D., Bosco, D. et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin. Endocrinol. Metab., 2005, 90(1), s. 501–506.
5. Schramm, T. K., Gislason, G. H., Vaag, A. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without previous myocardial infarction: a nationwide study. Eur Heart J., 2011, 32(15), s. 1900–1908.
6. Gunaratne, K., Austin, E., Wu, P. E. Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report. BMC Res Notes, 2018, 21, 11(1), s. 331. doi: 10.1186/s13104-018-3404-8.
7. Parekh, T. M., Raji, M., Lin, Y. L. et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med., 2014, 174(10), s. 1605–1612.
8. Scheen, A. J. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet, 2010, 49(9), s. 573–588.
9. SPC přípravku Trajenta (linagliptin), Boehringer Ingelheim, 2016. Dostupné na www: http://www.sukl.cz/modules/medication/search.php.
10. FDA Label information Tradjenta, 2017, USA. Dostupné na www: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201280s016lbl.pdf.
11. SPC přípravku Vipidia (sitatgliptin), Takeda Pharma, 2015. Dostupné na www: http://www.sukl.cz/modules/medication/search.php.
12. Itkonen, M. K., Tornio, A., Neuvonen, M. et al. Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. Drug Metab Dispos., 2016, 44(8), s. 1364–1371.
13. Tornio, A., Niemi, M., Neuvonen, P. J., Backman, J. T. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos., 2008, 36(1), s. 73–80.
14. Jaakkkolla, T., Backman, J. T., Neuvonen, M. et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol., 2006, 61(1), s. 70–78.
15. Niemi, N., Neuvonen, P. J., Kivistö, K. T. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther., 2001, 70(1), s. 58–65.
16. Niemi, N., Backman, J. T., Neuvonen, M., Neuvonen, P. J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46(3), s. 347–351.
17. Niemi, M., Jajosaari, L. I., Neuvonen, M. et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol., 2004, 57(4), s. 441–447.
18. SPC přípravku Novonorm (repaglinid), Novo Nordisk, 2016. Dostupné na www: http://www.sukl.cz/modules/medication/search.php.
19. Zhang, X. L., Zhu, Q. Q., Chen, Y. H. et al. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. J Am Heart Assoc., 2018, 20;7(2). pii: e007165. doi: 10.1161/JAHA.117.007165.
20. SPC ČR: Invokana® (kanagliflozin), Janssen-Cilag, 10/2018. Dostupné na www: https://www.ema.europa.eu/documents/product-information/invokana-epar-product-information_cs.pdf.
21. SPC ČR: Forxiga® (dapagliflozin), AstraZeneca, 12/2017. Dostupné na www: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf.
22. SPC ČR: Jardiance® (empagliflozin), Boehringer Ingelheim, 6/2018. Dostupné na www: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf.
23. Australian Public Assessment Report for Dapagliflozine propanediol monohydrate, 2013. Dostupné na www: https://www.tga.gov.au/sites/default/files/auspar-dapagliflozin-propanediol-monohydrate-130114.pdf, vstup 27.7.2018.
24. FDA Full Prescribing Information (USA): Invokana® (kanagliflozin), Janssen Pharms, 7/2017. Dostupné na www: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204042s026lbl.pdf.
25. FDA Full Prescribing Information (USA): Farxiga® (dapagliflozin), AstraZeneca, 10/2017. Dostupné na www: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s012lbl.pdf.
26. FDA Full Prescribing Information (USA): Jardiance® (empagliflozin), Boehringer Ingelheim, 12/2017. Dostupné na www: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204629s016lbl.pdf.
27. Prieto-García, L., Pericacho, M., Sancho-Martínez, S. M. et al. Mechanismus of triple whammy acute kidney injury. Pharmacol Ther., 2016, 167, s. 132–145. doi: 10.1016/j.pharmthera.2016.07.011. Epub 2016 Aug 1.
28. Mandal, E. K., Market, R. J., Saklayen, M. G. et al. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol., 1994, 42(3), s. 170–174.
29. No autors listed: ACE inhibitor, diuretic and NSAID: a dangerous combination. ADRAC bulletin, 2003, 22 (4), s. 14–15.
30. Carmin, R. M., Cols, M., Chevarria, J. L. et al. Acuta kidney injury secondary to combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: „The Triple Whammy“. Nefrologia, 2015, 35(2), s. 197–206.
31. Juurlink, D. N., Mamdani, M. M., Lee, D. S. et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med., 2004, 351(6), s. 543–551.
32. Prokeš, M., Suchopár, J. Léky ovlivňující renin-angiotenzinový systém, diuretika a kalemie: jsme dostatečně opatrní? Med. Praxi, 2014, 11(3), s. 127–130.
Štítky
Medical assessment Occupational medicineČlánok vyšiel v časopise
Medical Revision
2018 Číslo 3-4
Najčítanejšie v tomto čísle
- Experience from controls and revisions of correctness and rightfulness of NOAC prescription
- New and classical antidiabetics in 2018
- Assessment of health state in persons with breast cancer
- Method of self-image in assessment activity